| CNTX |
Context Therapeutics Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$8.91M |
$72.1K |
9.2M |
+0.82% |
Avidity Partners Management LP |
Sep 30, 2025 |
| SCYX |
Scynexis, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$3.48M |
$235K |
4.52M |
+7.24% |
Avidity Private Master Fund I LP |
Sep 30, 2025 |
| SYRS |
Syros Pharmaceuticals, Inc. |
Common Stock, $0.001 par value |
7.6% |
$61.4K |
|
2.05M |
|
Avidity Partners Management LP |
Dec 31, 2024 |
| KZR |
Kezar Life Sciences, Inc. |
Common Stock, par value $0.001 per share |
6.9% |
$397K |
|
503K |
|
Avidity Partners Management LP |
Dec 31, 2024 |
| DNTH |
Dianthus Therapeutics, Inc. |
Common Stock, $0.001 par value |
4.9% |
$71M |
-$43M |
2.1M |
-37.7% |
Avidity Partners Management LP |
Nov 17, 2025 |
| IMUX |
Immunic, Inc. |
Common Stock, $0.0001 par value |
4.8% |
$4.14M |
-$808K |
4.7M |
-16.3% |
Avidity Partners Management LP |
Sep 30, 2025 |
| CATX |
Perspective Therapeutics, Inc. |
Common Stock, $0.001 par value |
4.2% |
$6.9M |
|
2.84M |
|
Avidity Partners Management LP |
Dec 31, 2024 |
| KZR |
Kezar Life Sciences, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
Avidity Partners Management LP |
Sep 30, 2025 |